A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Recruiting · Phase 1, Phase 2 · NCT06618287
Conditions: Lung Cancer, Breast Cancer
At a glance
- Research payments reported, 2025
- $913
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 416
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986507 (drug), Osimertinib (drug), Pembrolizumab (drug), Nivolumab (drug), Pumitamig (drug)
- Dates
- Started 2025-02-04; completion 2031-02-26
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $913 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Miami Hospital $913
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.